AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33384402 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19-related prenatal stress exposure
Number of subjects: 0
Study 33384402 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective data on COVID-19-related stress during pregnancy
Number of subjects: 0
Study 33384402 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped semistructured interaction at 12 months
Number of subjects: 0
Study 33384640 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week visual art training program
Number of subjects: 53
Study 33384959 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based supportive care program
Number of subjects: 0
Study 33385020 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics; specific dosage and duration not available
Number of subjects: 0
Study 33385020 — intervention group
Group type: COMPARATOR
Intervention: Control group; specific details not available
Number of subjects: 0
Study 33385126 — intervention group
Group type: EXPERIMENTAL
Intervention: ENGBD
Number of subjects: 22
Study 33385126 — intervention group
Group type: COMPARATOR
Intervention: PTGBD
Number of subjects: 22
Study 33385266 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive housing with comprehensive health-related services
Number of subjects: 0
Study 33385266 — intervention group
Group type: EXPERIMENTAL
Intervention: Stakeholder strategies in supportive housing
Number of subjects: 0
Study 33385520 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor therapy
Number of subjects: 1214
Study 33385520 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy
Number of subjects: 1214
Study 33385520 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rate
Number of subjects: 1214
Study 33385520 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events (TRAEs)
Number of subjects: 1214
Study 33386133 — intervention group
Group type: EXPERIMENTAL
Intervention: Canonical variates related to multiple symptom dimensions (irritability, ADHD, anxiety)
Number of subjects: 508
Study 33386133 — intervention group
Group type: EXPERIMENTAL
Intervention: Canonical variates specific to anxiety
Number of subjects: 508
Study 33386133 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity modeled as partial correlations among 216 brain areas
Number of subjects: 508
Study 33386410 — intervention group
Group type: EXPERIMENTAL
Intervention: Employed participants
Number of subjects: 2481
Study 33386410 — intervention group
Group type: EXPERIMENTAL
Intervention: Household size
Number of subjects: 2481
Study 33386410 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 2481
Study 33386410 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2481
Study 33386970 — intervention group
Group type: EXPERIMENTAL
Intervention: Acromegaly group
Number of subjects: 52
Study 33386970 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 33387056 — intervention group
Group type: EXPERIMENTAL
Intervention: DeRidder Burst-SCS stimulation
Number of subjects: 0
Study 33387217 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid intradialytic exercise training (aerobic cycling and resistance training) for 9 months
Number of subjects: 20
Study 33387276 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-derived screening tool for food addiction (FA)
Number of subjects: 176
Study 33387276 — intervention group
Group type: EXPERIMENTAL
Intervention: Naive Bayes classification
Number of subjects: 176
Study 33387276 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-item nomogram
Number of subjects: 176
Study 33387373 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM) with the InterStim™ system
Number of subjects: 221
Study 33387381 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs)
Number of subjects: 1601
Study 33387490 — intervention group
Group type: EXPERIMENTAL
Intervention: APX005M (sotigalimab) with gemcitabine plus nab-paclitaxel, with or without nivolumab
Number of subjects: 30
Study 33388360 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Number of subjects: 650
Study 33388360 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 650
Study 33388360 — intervention group
Group type: EXPERIMENTAL
Intervention: External Radiation Therapy
Number of subjects: 650
Study 33388386 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diabetes
Number of subjects: 603
Study 33388386 — intervention group
Group type: COMPARATOR
Intervention: Patients without diabetes
Number of subjects: 603
Study 33388955 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic (VATS) resection
Number of subjects: 73
Study 33388985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implant fitting methodology and parameters
Number of subjects: 97
Study 33389082 — intervention group
Group type: EXPERIMENTAL
Intervention: Slower eating rate
Number of subjects: 33
Study 33389082 — intervention group
Group type: COMPARATOR
Intervention: Faster eating rate
Number of subjects: 33
Study 33389140 — intervention group
Group type: EXPERIMENTAL
Intervention: Breaks in sedentary time per sedentary hour (BST-ST)
Number of subjects: 80
Study 33389140 — intervention group
Group type: EXPERIMENTAL
Intervention: Bouts of sedentary time longer than 15 minutes (BSB > 15 min)
Number of subjects: 80
Study 33389140 — intervention group
Group type: COMPARATOR
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 80
Study 33389140 — intervention group
Group type: COMPARATOR
Intervention: Cardiorespiratory fitness (CRF)
Number of subjects: 80
Study 33389209 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmolality-based normalization
Number of subjects: 40
Study 33389209 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific dilution prior to analysis
Number of subjects: 40
Study 33389209 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of various normalization methods
Number of subjects: 40
Study 33389355 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure performance measurement variables (MDPE and MDAPE) during cardiac surgery
Number of subjects: 1203
Study 33389355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative hypotension measured by performance measurement variables
Number of subjects: 1203
Study 33389355 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaplan-Meier survival curves
Number of subjects: 1203
Study 33389379 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted reproductive technology (ART) after ovarian tissue transplantation (OTT)
Number of subjects: 11
Study 33389379 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous conception
Number of subjects: 11
Study 33389388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulixertinib (10 to 900 mg in dose escalation cohort, 600 mg in 21-day cycles in expansion cohort)
Number of subjects: 135
Study 33389459 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salt-low protein diet (0.6 g/kg-day) supplemented with keto-analogues (sLPD) under intensive nutritional counselling
Number of subjects: 92
Study 33389656 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib (27 mg/m²) administered twice weekly
Number of subjects: 0
Study 33390187 — intervention group
Group type: EXPERIMENTAL
Intervention: Education on one occasion
Number of subjects: 20
Study 33390187 — intervention group
Group type: EXPERIMENTAL
Intervention: Education staged and supported by a dietitian
Number of subjects: 20
Study 33390187 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 33390782 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin
Number of subjects: 0
Study 33390782 — intervention group
Group type: EXPERIMENTAL
Intervention: Torin-2
Number of subjects: 0
Study 33390782 — intervention group
Group type: EXPERIMENTAL
Intervention: RIST treatment protocol (combination of Rapamycin and Dasatinib with Irinotecan and Temozolomide)
Number of subjects: 0
Study 33390917 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS on the anterior cingulate cortex
Number of subjects: 20
Study 33390917 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 33391002 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml of 5% dextrose water
Number of subjects: 63
Study 33391002 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml of 5% dextrose water
Number of subjects: 63
Study 33391002 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml of 5% dextrose water
Number of subjects: 63
Study 33391002 — intervention group
Group type: COMPARATOR
Intervention: Electrophysiological studies
Number of subjects: 63
Study 33391002 — intervention group
Group type: COMPARATOR
Intervention: Median nerve CSA
Number of subjects: 63
Study 33391029 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous physical activity (PA)
Number of subjects: 262
Study 33391029 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased systolic blood pressure (BP)
Number of subjects: 262
Study 33391029 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 262
Study 33391164 — intervention group
Group type: EXPERIMENTAL
Intervention: CareToy-Revised (CareToy-R) intervention for 8 weeks
Number of subjects: 19
Study 33392384 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA imaging
Number of subjects: 193
Study 33392438 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient and family co-developed participant information
Number of subjects: 0
Study 33392485 — intervention group
Group type: EXPERIMENTAL
Intervention: INO-4800 1.0 mg
Number of subjects: 40
Study 33392485 — intervention group
Group type: EXPERIMENTAL
Intervention: INO-4800 2.0 mg
Number of subjects: 40
Study 33392485 — intervention group
Group type: EXPERIMENTAL
Intervention: INO-4800
Number of subjects: 40
Study 33392493 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors 1 (Interferon-gamma, IL-4, IL-7, IL-10, IL-12, IL-17A, IL-21, IL-23, MIP-1α, MIP-1β, TNF-α, GM-CSF)
Number of subjects: 358
Study 33392493 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors 2 (IL-5, IL-6, IL-8, IL-13)
Number of subjects: 358
Study 33392493 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors 1, 2 and 3 (C-Reactive protein, IL-1β, IL-2, MIP-3α)
Number of subjects: 358
Study 33392493 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerous individual inflammatory mediators (Interferon-gamma, GM-CSF, IL-4, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17A, IL-21, IL-23, MIP-1α, MIP-1β)
Number of subjects: 358
Study 33392541 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil-containing lipid injectable emulsion (Smoflipid 20% lipid emulsion) administered at doses of 1.0 to 1.6 g/kg within 48 hours of enrollment.
Number of subjects: 10
Study 33392749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg once daily
Number of subjects: 34
Study 33392770 — intervention group
Group type: EXPERIMENTAL
Intervention: Care pathway (PP)
Number of subjects: 48
Study 33392770 — intervention group
Group type: COMPARATOR
Intervention: Standard care (NPP)
Number of subjects: 48
Study 33392801 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemafibrate
Number of subjects: 0
Study 33392801 — intervention group
Group type: COMPARATOR
Intervention: Statins
Number of subjects: 0
Study 33393377 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment intervention
Number of subjects: 0
Study 33393488 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 277
Study 33393488 — intervention group
Group type: COMPARATOR
Intervention: Nonstatin users (Control)
Number of subjects: 277
Study 33393488 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin and Nonstatin users (Control)
Number of subjects: 277
Study 33394100 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity aerobic exercise for 8 weeks
Number of subjects: 0
Study 33394100 — intervention group
Group type: COMPARATOR
Intervention: Antiparkinsonian medication
Number of subjects: 0
Study 33394121 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dietary zinc intake (8.4±4.5 mg/day) from non-red meat sources
Number of subjects: 5186
Study 33394121 — intervention group
Group type: COMPARATOR
Intervention: Dietary zinc intake from red meat sources
Number of subjects: 5186
Study 33394138 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracker
Number of subjects: 24
Study 33394138 — intervention group
Group type: COMPARATOR
Intervention: Diary
Number of subjects: 24
Study 33394284 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA ligand
Number of subjects: 42
Study 33394595 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative assessment of allograft microperfusion using indocyanine green (ICG) fluorescence angiography
Number of subjects: 128
Study 33394595 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG Ingress
Number of subjects: 128
Study 33394679 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected women not on ART
Number of subjects: 207
Study 33394679 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline vaginal inflammation
Number of subjects: 207
Study 33394722 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy using modern agents (e.g., oral hypomethylating agents, protein modifiers, FLT3, IDH1/2, BCL-2, immune checkpoint inhibitors)
Number of subjects: 0
Study 33394722 — intervention group
Group type: COMPARATOR
Intervention: Randomized, placebo-controlled trials of maintenance therapy
Number of subjects: 0
Study 33394878 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathic pain (NeuP)
Number of subjects: 66
Study 33394878 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned pain modulation
Number of subjects: 66
Study 33394878 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-parent QoL scores
Number of subjects: 66
Study 33394925 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing myopic spherical refractive errors
Number of subjects: 2212
Study 33394925 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing astigmatic refractive errors
Number of subjects: 2212
Study 33394925 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher uncorrected hyperopic refractive error
Number of subjects: 2212
Study 33394925 — intervention group
Group type: EXPERIMENTAL
Intervention: logMAR distance acuity of 0.20 to 0.32
Number of subjects: 2212
Study 33394925 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance acuity alone
Number of subjects: 2212
Study 33394925 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher myopic and/or astigmatic refractive errors
Number of subjects: 2212
Study 33394925 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in acuity per diopter of cylindrical error
Number of subjects: 2212
Study 33394925 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance acuity
Number of subjects: 2212
Study 33394925 — intervention group
Group type: EXPERIMENTAL
Intervention: Accommodation
Number of subjects: 2212
Study 33394942 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare professional priorities
Number of subjects: 144
Study 33394942 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent priorities
Number of subjects: 144
Study 33394942 — intervention group
Group type: COMPARATOR
Intervention: Comparison of priorities
Number of subjects: 144
Study 33395032 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (Koselugo) for plexiform neurofibromas (pNF)
Number of subjects: 71
Study 33395032 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (Koselugo) for low-grade gliomas (LGG)
Number of subjects: 71
Study 33395094 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid multiplex-PCR assays for pneumonia diagnosis
Number of subjects: 0
Study 33395094 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid multiplex-PCR assays
Number of subjects: 0
Study 33395098 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel genetic therapies
Number of subjects: 0
Study 33395098 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of UBE3A and its role in neuronal development
Number of subjects: 0
Study 33395098 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater understanding of the pathophysiology of different phenotypes
Number of subjects: 0
Study 33395354 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33395553 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive Ventilatory Support
Number of subjects: 0
Study 33397139 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 30
Study 33397139 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.045 mg/kg)
Number of subjects: 30
Study 33397330 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 58
Study 33397350 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended scope physiotherapists (ESP)
Number of subjects: 69
Study 33397350 — intervention group
Group type: COMPARATOR
Intervention: Orthopaedic surgeons (OS)
Number of subjects: 69
Study 33397350 — intervention group
Group type: EXPERIMENTAL
Intervention: ESP and OS combined
Number of subjects: 69
Study 33397382 — intervention group
Group type: EXPERIMENTAL
Intervention: Care pathway (CP) implementation
Number of subjects: 381
Study 33397509 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist supplemented care
Number of subjects: 356
Study 33397509 — intervention group
Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 356
Study 33397511 — intervention group
Group type: EXPERIMENTAL
Intervention: Sawyer® PointONE™ filters installed in homes
Number of subjects: 16
Study 33397511 — intervention group
Group type: COMPARATOR
Intervention: Sawyer® PointONE™ filters installed in schools
Number of subjects: 16
Study 33398064 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 47
Study 33398260 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom management care pathways
Number of subjects: 0
Study 33398260 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33398536 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary glioma cell lines
Number of subjects: 12
Study 33398548 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI) + White Light (WL)
Number of subjects: 84
Study 33398548 — intervention group
Group type: COMPARATOR
Intervention: White Light (WL)
Number of subjects: 84
Study 33398714 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hyperoxemia (PaO2: 120-200 mmHg, n = 121)
Number of subjects: 247
Study 33398714 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hyperoxemia (PaO2: > 200 mmHg, n = 74)
Number of subjects: 247
Study 33398714 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (PaO2 < 120 mmHg, n = 52)
Number of subjects: 247
Study 33399311 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP candidates (51.8% precontemplative, 48.2% contemplative)
Number of subjects: 1398
Study 33399311 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP action (3.1% reached stage 4; prescribed PrEP)
Number of subjects: 1398
Study 33399311 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP maintenance (87% adherence to 4+ doses per week)
Number of subjects: 1398
Study 33399311 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with reaching later stages
Number of subjects: 1398
Study 33399372 — intervention group
Group type: EXPERIMENTAL
Intervention: mini-fluid challenge (mini-FC) of 100 ml over 1 min
Number of subjects: 103
Study 33399372 — intervention group
Group type: COMPARATOR
Intervention: end-expiratory occlusion test (EEOT20)
Number of subjects: 103
Study 33399372 — intervention group
Group type: COMPARATOR
Intervention: end-expiratory occlusion test (EEOT30)
Number of subjects: 103
Study 33399375 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative moderate to severe anaemia
Number of subjects: 8264
Study 33399383 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% inhaled N2O
Number of subjects: 40
Study 33399383 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% inhaled N2O
Number of subjects: 40
Study 33399433 — intervention group
Group type: EXPERIMENTAL
Intervention: Open schools and day-care facilities
Number of subjects: 0
Study 33399511 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided focused ultrasound-induced BBB opening targeting the hippocampus and entorhinal cortex, performed three times at 2-week intervals using a 220-kHz transducer and intravenous microbubble contrast agent.
Number of subjects: 3
Study 33400032 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured MRI template report including 8 key descriptors of anal fistulas
Number of subjects: 0
Study 33400164 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing home residents with COVID-19
Number of subjects: 0
Study 33400164 — intervention group
Group type: EXPERIMENTAL
Intervention: General population with COVID-19
Number of subjects: 0
Study 33400438 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral oblique view (CLO) at 60 degrees
Number of subjects: 30
Study 33400438 — intervention group
Group type: COMPARATOR
Intervention: Contralateral oblique view (CLO) at 40 degrees
Number of subjects: 30
Study 33400438 — intervention group
Group type: COMPARATOR
Intervention: Contralateral oblique view (CLO) at 50 degrees
Number of subjects: 30
Study 33400438 — intervention group
Group type: COMPARATOR
Intervention: Contralateral oblique view (CLO) at 90 degrees
Number of subjects: 30
Study 33400438 — intervention group
Group type: COMPARATOR
Intervention: Lateral view
Number of subjects: 30
Study 33400439 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care with visit frequency more than once per week for CLBP
Number of subjects: 2576
Study 33400439 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care with visit frequency (general)
Number of subjects: 2576
Study 33400439 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care (general)
Number of subjects: 2576
Study 33400777 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral agents (DAA) treatment
Number of subjects: 50861
Study 33400907 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33401131 — intervention group
Group type: EXPERIMENTAL
Intervention: Bending trunk test
Number of subjects: 0
Study 33401131 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit to Stand test
Number of subjects: 0
Study 33401131 — intervention group
Group type: EXPERIMENTAL
Intervention: Sock test
Number of subjects: 0